Press release
Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
HOLON, Israel, Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and a
About this update from Compugen Ltd.
[{"type":"text","content":"HOLON, Israel, Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), (\"Compugen\", the \"Company\"), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb, to its Board of Directors effective March 1, 2022. In addition, the Company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors.\n\"I am delighted to welcome Math to Compugen's Board,\" said Paul Sekhri, Chairman of the Board. \"His considerable experience in immuno-oncology drug development including involvement in five break-through designation applications for IO therapies to treat life-threatening cancers is invaluable as we continue progressing our innovative pipeline of potential first-in-class immuno-oncology drugs aimed at addressing novel drug targets discovered computationally by Compugen. I would also like to thank Jean-Pierre who will end his tenure as a director on March 1, 2022, for his contributions to Compugen.\"\n\"I had the privileged opportunity to play a key role in the introduction of transformational immune-based therapies that are today changing patients' lives. But more needs to be done, as many patients are resistant to these therapies. This is what excites me about the work being conducted at Compugen in understanding immune-resistance through their ground-breaking research on the DNAM-1 axis, specifically PVRIG and TIGIT. I look forward to working with the board and management at Compugen, to bring the next potentially first-in-class immunotherapies to patients with the greatest urgency, many of whom do not have time to wait,\" said Math Hukkelhoven, Ph.D.\nDr. Hukkelhoven has a wealth of experience in global regulatory affairs and drug development, evidenced by his contribution to more than 50 NCEs and hundreds of new indications and line extensions over his career to date. Dr. Hukkelhoven has participated in activities that have shaped health authority interactions for the industry, including serving as chairperson of the Regulatory Affairs Coordinating Committee at PhRMA, and recently as a PhRMA negotiator for the PDUFA VII negotiations with the FDA. Since his retirement from Bristol Myers Squibb in July 2021, Math has be...